Results 11 to 20 of about 5,353 (192)

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells

OncoImmunology, 2023
Chimeric antigen receptor (CAR)-T cells have not made significant progress in the treatment of acute myeloid leukemia (AML) in earlyclinical studies. This lack of progress could be attributed in part to the immunosuppressive microenvironment of AML, such
Xin Jin, Danni Xie, Rui Sun, Wenyi Lu, Xia Xiao, Yibing Yu, Juanxia Meng, Mingfeng Zhao   +7 more
doaj   +2 more sources

Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia [PDF]

Neoplasia: An International Journal for Oncology Research, 2018
Leukemic stem cells (LSCs) are an emerging target of curative anti-leukemia therapy. In acute lymphoblastic leukemia (ALL), LSCs frequently express CD34 and often lack CD38. However, little is known about markers and targets expressed in ALL LSCs.
Katharina Blatt, Ingeborg Menzl, Gregor Eisenwort, Sabine Cerny-Reiterer, Harald Herrmann, Susanne Herndlhofer, Gabriele Stefanzl, Irina Sadovnik, Daniela Berger, Alexandra Keller, Alexander Hauswirth, Gregor Hoermann, Michael Willmann, Thomas Rülicke, Heinz Sill, Wolfgang R. Sperr, Christine Mannhalter, Junia V. Melo, Ulrich Jäger, Veronika Sexl, Peter Valent   +20 more
doaj   +2 more sources

Phenotypic characterization of malignant progenitor cells in patients with idiopathic myelofibrosis

Hematology/Oncology and Stem Cell Therapy, 2019
Objective/Background: Idiopathic myelofibrosis (IM) is a clonal hematological malignancy originating from pluripotent hematopoietic stem cells (HSC). HSC are very rare potent cells that reside in the bone marrow (BM) and at a lower level in peripheral ...
Yonghua Bao, Wenyang Hu, Yongchen Guo, Wancai Yang   +3 more
doaj   +2 more sources

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells [PDF]

, 2021
NPM1-mutated (NPM1mut) acute myeloid leukemia (AML) comprises about 30% of newly diagnosed AML in adults. Despite notable advances in the treatment of this frequent AML subtype, about 50% of NPM1mut AML patients treated with conventional treatment die ...
Andrea Marra, Alessandro Rambaldi, Maria Paola Martelli, Ilaria Gionfriddo, Orietta Spinelli, Brunangelo Falini, Federica Mezzasoma, Francesca Milano, Giuseppe Avvisati, Lorenzo Brunetti, Francesco Di Raimondo, Ombretta Annibali, Stefano Ascani, Vincenzo Maria Perriello, Roberta Rossi   +14 more
core   +2 more sources

Acute Myeloid Leukemia With Florid Plasmacytoid Dendritic Cell Expansion and Aberrant Expression of CD19. [PDF]

Int J Lab Hematol
International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 919-920, October 2026.
Shameli A, Dorer RK.
europepmc   +2 more sources

Survival outcomes of CD34+CD38−LSCs and their expression of CD123 in adult AML patients [PDF]

Oncotarget, 2018
Acute myeloid leukemia (AML) is one of the most common leukemias in adults. AML is generally regarded as a stem cell disease characterized by an accumulation of undifferentiated and functionally heterogeneous populations of cells, The aim of the present study was to identify leukemia stem cells in patients with AML and their correlations with treatment
Zahran, Asmaa M., Aly, Sanaa Shaker, Rayan, Amal, El-Badawy, Omnia, Fattah, Maged Abdel, Ali, Arwa Mohammed, ElBadre, Hala M., Hetta, Helal F.   +7 more
openaire   +2 more sources

Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia

Frontiers in Oncology, 2022
Acute myeloid leukemia (AML) is a heterogenous disease in which the initiation and maintenance of the malignant clone is blamed on a rare population of leukemia stem cells (LSCs).
Azza M. Kamel, Nahla M. Elsharkawy, Eman Z. Kandeel, Marwa Hanafi, Mohammed Samra, Randa A. Osman   +5 more
doaj   +1 more source

IMMUNPHETONYPING PANEL REPOSITIONING: NEW WAYS TO ANALYZE ACUTE MYELOID LEUKEMIA BIOMARKERS AND THEIR RELEVANCE

Hematology, Transfusion and Cell Therapy, 2023
One of the greatest obstacles in the treatment of Acute Myeloid Leukemia (AML) is relapse, occurring in 40-50% of younger patients and most elderly patients.
CK Dias, HC Alves, MFGM Fernandes, AN Sant'ana, MG Farias, AP Alegretti, PP Silva, LE Daudt, AA Paz, MB Michalowski, F Figueiró   +10 more
doaj   +1 more source

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA

Frontiers in Oncology, 2022
APVO436 is a recombinant bispecific antibody designed to direct host cytotoxic T-cells to CD123-expressing blast cells in patients with hematologic malignancies. APVO436 showed promising tolerability and single-agent activity in relapsed or refractory (R/
Justin Watts, Tara L. Lin, Alice Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul Shami, Elizabeth Cull, Christopher R. Cogle, Eunice Wang, Fatih M. Uckun, Fatih M. Uckun   +11 more
doaj   +1 more source

A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3 -Mutated Clones in Acute Myeloid Leukemia [PDF]

Clinical Cancer Research, 2015
Abstract Purpose: We evaluated leukemia-associated immunophenotypes (LAIP) and their correlation with fms-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1) gene mutational status in order to contribute a better identification of patients at highest risk of relapse in acute myeloid leukemia (AML).
Angelini D, Ottone T, Guerrera G, Lavorgna S, Cittadini M, BUCCISANO, FRANCESCO, De Bardi M, Gargano F, Maurillo L, Divona M, Noguera NI, Irno Consalvo M, Borsellino G, Bernardi G, AMADORI, SERGIO, VENDITTI, ADRIANO, Battistini L, LO COCO, FRANCESCO   +17 more
openaire   +3 more sources